Phathom Pharmaceuticals
PHAT
61 hedge funds and large institutions have $719M invested in Phathom Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
30% more funds holding
Funds holding: 47 → 61 (+14)
27% more capital invested
Capital invested by funds: $566M → $719M (+$153M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
0.36% less ownership
Funds ownership: 75.77% → 75.41% (-0.36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$9.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.81M |
| 4 |
JP Morgan Chase
New York
|
+$6.02M |
| 5 |
BlackRock
New York
|
+$5.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$56M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$13.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$3.42M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$485K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$430K |
PHAT Hedge Fund Activity: Q2 2020 in Review
61 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2020, worth a combined $719M — up 27% from $566M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PHAT positions and 6 closed out — a net gain of 14 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $19M. The largest seller was Frazier Management, cutting an estimated $56M.
- 61 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2020, up from 47 in Q1 2020.
- Funds reported $719M of Phathom Pharmaceuticals stock for Q2 2020, up 27% quarter-over-quarter.
- 20 funds opened new Phathom Pharmaceuticals positions in Q2 2020 and 6 closed out, a net change of +14 holders.
- The largest Phathom Pharmaceuticals buyer in Q2 2020 was Vanguard Group, an estimated $19M added.
- The largest Phathom Pharmaceuticals seller in Q2 2020 was Frazier Management, an estimated $56M sold.
Based on aggregated 13F filings for Q2 2020.